ATE310514T1 - Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen - Google Patents

Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen

Info

Publication number
ATE310514T1
ATE310514T1 AT03746878T AT03746878T ATE310514T1 AT E310514 T1 ATE310514 T1 AT E310514T1 AT 03746878 T AT03746878 T AT 03746878T AT 03746878 T AT03746878 T AT 03746878T AT E310514 T1 ATE310514 T1 AT E310514T1
Authority
AT
Austria
Prior art keywords
groups
oxygen species
treatment
agonist compounds
nitrogen oxide
Prior art date
Application number
AT03746878T
Other languages
German (de)
English (en)
Inventor
Abdullah Ibrahim Haj-Yehia
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE310514T1 publication Critical patent/ATE310514T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03746878T 2002-04-19 2003-04-15 Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen ATE310514T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37417302P 2002-04-19 2002-04-19
PCT/IL2003/000312 WO2003088961A1 (en) 2002-04-19 2003-04-15 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
ATE310514T1 true ATE310514T1 (de) 2005-12-15

Family

ID=29251152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746878T ATE310514T1 (de) 2002-04-19 2003-04-15 Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen

Country Status (7)

Country Link
US (2) US7378438B2 (enExample)
EP (1) EP1503754B1 (enExample)
JP (1) JP2005533013A (enExample)
AT (1) ATE310514T1 (enExample)
AU (1) AU2003226603A1 (enExample)
DE (1) DE60302454T2 (enExample)
WO (1) WO2003088961A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310514T1 (de) 2002-04-19 2005-12-15 Yissum Res Dev Co Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
JP2006206521A (ja) * 2005-01-28 2006-08-10 Univ Of Tokyo 一酸化窒素供与体としてのn−ニトロソアミン化合物
TWI645031B (zh) * 2005-06-24 2018-12-21 哈尼威爾國際公司 含有經氟取代之烯烴之組合物及其用途
GB0708392D0 (en) * 2007-05-01 2007-06-06 Clearway Medical Ltd Breathing device
WO2011092690A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
WO2012037665A1 (en) * 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012093383A1 (en) * 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
CN103018452B (zh) * 2011-09-20 2016-01-13 北京勤邦生物技术有限公司 一种检测沙丁胺醇药物的胶体金试纸卡及检测方法
WO2014169976A1 (en) * 2013-04-18 2014-10-23 Nicox Science Ireland Quinone based nitric oxide donating compounds
US10064583B2 (en) 2013-08-07 2018-09-04 Covidien Lp Detection of expiratory airflow limitation in ventilated patient
HK1223561A1 (zh) 2013-08-23 2017-08-04 帕里昂科学公司 二巯基化物类粘液溶解剂
MX387071B (es) 2015-01-30 2025-03-19 Parion Sciences Inc Agentes mucolíticos de monotiol novedosos
US10441568B2 (en) * 2015-03-26 2019-10-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nitroxide radicals for the treatment of diseases of the respiratory tract
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ
WO2018067838A1 (en) * 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
CA3048785A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2018178902A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
JP2021503029A (ja) 2017-11-15 2021-02-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 抗菌性足場としての一酸化窒素放出性超分岐化合物およびそれに関する方法
AU2019231712B2 (en) 2018-03-06 2025-04-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3902841B1 (en) 2018-12-28 2025-01-29 The University of North Carolina at Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
CN112745251B (zh) * 2019-10-31 2023-10-27 华创合成制药股份有限公司 一种治疗祛痰化合物及其制备方法和用途
WO2022251679A1 (en) * 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US6297762B1 (en) 1979-06-27 2001-10-02 Raytheon Company Electronic countermeasures system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
WO1990013327A1 (en) 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
JP3085705B2 (ja) 1990-01-05 2000-09-11 セプラカー・インコーポレーテツド 喘息の治療のための光学的純粋r(−)アルブテロール
US5364833A (en) 1990-05-09 1994-11-15 Basf Aktiengesellschaft Cyclohexenone oxime ethers, their preparation and their use as herbicides
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5821259A (en) 1991-11-12 1998-10-13 Theoharides; Theoharis C. H3 -receptor agonists as therapeutic agents
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5277195A (en) 1992-02-03 1994-01-11 Dura Pharmaceuticals, Inc. Portable spirometer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
KR0177265B1 (ko) 1992-10-19 1999-04-01 미첼 알. 우드베리 건분말 흡입기
US6131567A (en) 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
WO1994016756A1 (en) 1993-01-29 1994-08-04 Miris Medical Corporation Intrapulmonary delivery of hormones
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
WO1995030641A1 (en) 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5686878A (en) * 1995-04-03 1997-11-11 Gueli; Carmen Temperature sensitive fusible link assembly having cooperating projections and slots
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
AU2662799A (en) 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
AU775388B2 (en) 1998-11-25 2004-07-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
IL143726A0 (en) 1998-12-14 2002-04-21 Cellegy Pharma Inc A pharmaceutical composition containing a nitric oxide donor
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
CA2371927A1 (en) 1999-03-11 2000-09-14 The University Of Manitoba Nitric oxide manipulation of muscle satellite cell activation
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6492405B2 (en) 1999-12-30 2002-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nitric oxide donors and pharmaceutical compositions containing them
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
ATE310514T1 (de) 2002-04-19 2005-12-15 Yissum Res Dev Co Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen

Also Published As

Publication number Publication date
WO2003088961A1 (en) 2003-10-30
JP2005533013A (ja) 2005-11-04
DE60302454D1 (de) 2005-12-29
US7378438B2 (en) 2008-05-27
AU2003226603A1 (en) 2003-11-03
EP1503754B1 (en) 2005-11-23
US20050228184A1 (en) 2005-10-13
US20080149097A1 (en) 2008-06-26
DE60302454T2 (de) 2006-08-17
EP1503754A1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
ATE310514T1 (de) Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
DE69926665D1 (de) Azolo-Pyrimidine
DE60218445D1 (de) Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
WO2007085815A3 (en) Ligands that bind il-4 and/or il-13
ATE519489T1 (de) Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
BG108425A (en) Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2005016323A3 (en) Use of c-kit inhibitors for treating type ii diabetes
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
DE60234100D1 (de) Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
DE60223508D1 (de) Nicotinrezeptor-agonisten zur behandlung von entzündlichen lungenerkrankungen
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
MXPA05001573A (es) Combinacion novedosa de glucocorticoides e inhibidores de pde-4 para tratar enfermedades respiratorias, enfermedades alergicas, asma y copd.
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
SE9900834D0 (sv) Novel combination
ATE349210T1 (de) Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
DE50309777D1 (de) HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG
ATE455553T1 (de) Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
ATE447325T1 (de) Verwendung von einem polysaccharide zur erhöhung der toleranz gegen abiotische stress in pflanzen
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
DK1511466T3 (da) Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD
DE69504198D1 (de) Substituierte alkyldiaminderivate und ihre verwendung als tachykinin antagonisten
DE602005016406D1 (de) Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ödemerzeugung nach intrazerebraler hämorrhagie (ich)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties